Effect of ARVANIL (cas 128007-31-8) (N-arachidonoyl-vanillyl-amine), a nonpungent anandamide–capsaicin hybrid, on ion currents in NG108-15 neuronal cells

Add time:08/27/2019    Source:sciencedirect.com

The effects of ARVANIL (cas 128007-31-8) (N-arachidonoyl-vanillyl-amine), a structural hybrid between capsaicin and anandamide, on ion currents in a mouse neuroblastoma and rat glioma hybrid cell line, NG108-15, were examined with the aid of the whole-cell voltage-clamp technique. Arvanil (0.2–50 μM) caused an inhibition of voltage-dependent L-type Ca2+ current (ICa,L) in a concentration-dependent manner. Arvanil produced no change in the overall shape of the current–voltage relationship of ICa,L. The ic50 value of arvanil-induced inhibition of ICa,L was 2 μM. Arvanil (5 μM) could shift the steady-state inactivation curve of ICa,L to a more negative potential by approximately −15 mV. No effect of arvanil (20 μM) on delayed rectifier K+ current (IK(DR)) was observed; however, capsaicin (20 μM), glyceryl nonivamide (20 μM) and capsinolol (20 μM) suppressed it significantly. Arvanil (20 μM) caused a slight reduction in the amplitude of erg (ether-à-go-go-related)-mediated K+ current (IK(erg)) without modifying the activation curve of this current, while capsaicin and glyceryl nonivamide were more effective in suppressing IK(erg). Under current-clamp configuration, arvanil decreased the firing frequency of action potentials. Arvanil-mediated inhibition of ICa,L appeared to be independent of its binding to either vanilloid or cannabinoid receptors. The channel-blocking properties of arvanil may, at least in part, contribute to the underlying mechanisms by which it affects neuronal or neuroendocrine function.

We also recommend Trading Suppliers and Manufacturers of ARVANIL (cas 128007-31-8). Pls Click Website Link as below: cas 128007-31-8 suppliers

Prev:ARVANIL (cas 128007-31-8) and anandamide up-regulate CD36 expression in human peripheral blood mononuclear cells
Next:ARVANIL (cas 128007-31-8)-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB1/CB2 receptors)